This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torres-Viera, C.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torres-Viera, C.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1720-1724, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis

C. Torres-Viera,1,2 C. Thauvin-Eliopoulos,1,2 M. Souli,1,2 P. DeGirolami,1,2 M. G. Farris,1 C. B. Wennersten,1 R. D. Sofia,3 and G. M. Eliopoulos1,2,*

Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center,1 and Harvard Medical School,2 Boston, Massachusetts 02115, and Wallace Laboratories, Cranbury, New Jersey 085123

Received 30 August 1999/Returned for modification 24 November 1999/Accepted 21 March 2000

In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 µg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10-9) are favorable indicators for its possible development for topical use.

* Corresponding author. Mailing address: Department of Medicine, Beth Israel Deaconess Medical Center, 110 Francis St., Suite 6A, Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}caregroup.harvard.edu.

Antimicrobial Agents and Chemotherapy, June 2000, p. 1720-1724, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Sherertz, R. J., Boger, M. S., Collins, C. A., Mason, L., Raad, I. I. (2006). Comparative in vitro efficacies of various catheter lock solutions.. Antimicrob. Agents Chemother. 50: 1865-1868 [Abstract] [Full Text]  
  • Betjes, M. G. H., van Agteren, M. (2004). Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 19: 1546-1551 [Abstract] [Full Text]  
  • Shah, C. B., Mittelman, M. W., Costerton, J. W., Parenteau, S., Pelak, M., Arsenault, R., Mermel, L. A. (2002). Antimicrobial Activity of a Novel Catheter Lock Solution. Antimicrob. Agents Chemother. 46: 1674-1679 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»